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INTRODUCTION: Oral β-blockers improve the prognosis of patients with acute myocardial infarction, while atrial fibrillation 
worsens the prognosis of this population. The reduction of atrial fibrillation incidence in patients treated with β-blockers could at 
least in part explain the benefits of this drug. 
OBJECTIVE: To investigate the effect of β-blockers on the incidence of atrial fibrillation in patients with acute myocardial infarction. 
METHODS: We analyzed 1401 patients with acute myocardial infarction and evaluated the occurrence or absence of atrial fibril-
lation, the use of oral β-blockers and mortality during the first 24 hours. 
RESULTS: a) The use of β-blockers was inversely correlated with the presence of atrial fibrillation (ρ = 0.004; OR = 0.54). 
b) Correlations with mortality were as follows: 31.5% in patients with atrial fibrillation, 9.2% in those without atrial fibrilla-
tion (ρ < 0.001; Odds Ratio = 4.52), and 17.5% in patients not treated with β-blockers and 6.7% in those who received the drug 
(ρ < 0.001; OR = 0.34). c) Adjusted Models: The presence of atrial fibrillation was independently correlated with mortality 
(OR = 2.48, ρ = 0.002). The use of β-blockers was inversely and independently correlated with mortality (OR = 0.53; ρ = 0.002). 
The patients who used β-blockers showed a lower risk of atrial fibrillation (OR = 0.59; ρ = 0.029) in the adjusted model. 
CONCLUSION: The presence of atrial fibrillation and the absence of oral β-blockers increased in-hospital mortality in patients 
with acute myocardial infarction. Oral β-blockers reduced the incidence of atrial fibrillation, which might be at least partially 
responsible for the drug’s benefit.
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contraindications.
It has classically been accepted that the main mechanisms 
responsible for the beneficial effects of β-blockers involve 
blocking myocardial sympathetic stimulation, a decrease 
in heart rate and blood pressure and a benefit for heart 
remodeling.1 However, some recent publications have 
suggested that the reduction in the incidence of arrhythmias 
after AMI, seen after β-blocker treatment, could also have a 
leading role in explaining the benefits obtained with the use 
of these drugs.2,11-17 It is also well demonstrated that atrial 
fibrillation (AF) is considered a factor of poor prognosis in 
myocardial infarction, even in adjusted models.14,18-25
In this context, we analyzed data from 1401 patients with 
AMI in a single institution in order to investigate the effect 
of β-blockers on the incidence of AF and to analyze the 
relationships between mortality in 24 hours and 1) the use 
of β-blockers and 2) the incidence of AF.
INTRODUCTION
In the United States, more than one million people suffer 
an acute myocardial infarction (AMI) each year. Even with 
recent advances in diagnosis and treatment, global mortality 
rates are still around 30%.1 Several studies have shown that 
the early use of β-blockers in patients with AMI is able to 
limit the extent of myocardial injury and improve the short- 
and long-term prognosis.1-9 Thus, routine use of β-blockers 
is recommended in patients with AMI, provided there are no 
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METHODS
This study was a retrospective unicentric study. All 
included patients with AMI (n = 1401; median age = 63 
years) were hospitalized in a single coronary intensive 
care unit and were prospectively included in a specific 
database. The patients were analyzed during the first 24 
hours after hospitalization. The definitions and medical 
procedures followed the institutional routines, in accordance 
with recent guidelines. During this period, AF was treated 
with synchronized electrical cardioversion and the use of 
amiodarone in all patients.
A diagnosis of AMI was established when patients 
had chest pain at rest with concomitant ischemic ST-T 
changes and positive serum troponin.26 The left ventricular 
ejection fraction (LVEF) was calculated by Doppler 
echocardiography (Simpson). Only the period when patients 
were hospitalized was analyzed, taking into account the 
presence of AF, the use of oral β-blockers and all-cause 
mortality. Categorical variables were compared using 
Pearson’s chi-square test or Fisher’s exact test, as indicated. 
The Student’s t test was used to compare continuous 
variables. 
In adjusted models, the analyses were performed by 
stepwise logistic regression. In the first model, AF was 
included as a dependent variable. The adjusted R2 was 
0.114. The following variables were considered independent: 
LVEF, age, gender, previous diabetes mellitus, previous 
myocardial infarction, current myocardial infarction 
location, ST elevation, admission creatinine, coronary 
surgery and angioplasty during hospitalization, use of 
aspirin, angiotensin-converting enzyme inhibitor and use of 
β-blockers. In the second model, death was the dependent 
variable. AF was added to the other independent variables 
included in the first model. The adjusted R2 of this model 
was 0.226.
In all models, statistical significance was set at 5% (ρ < 
0.05).
RESULTS 
a. Population studied
As stated above, 1401 patients were examined. The 
average age of the population was 63.19 + 12.7 years 
and 1021 patients (72.9%) were men. The left ventricular 
ejection fraction was, on average, 51.1% + 15.5. During the 
hospitalization, 150 patients (10.7%) died.
b. Univariate analysis
b.1. Occurrence of AF
The baseline characters and univariate analysis of their 
association with AF is shown in Table 1. The use of β-blockers 
was inversely correlated with the presence of AF. As shown 
in Table 1, age, diabetes mellitus, previous AMI, coronary 
surgery, angioplasty, creatinine clearance and LVEF also had 
a significant correlation with the presence of AF. Excluding 
patients who used intravenous β-blockers followed by oral 
β-blockers did not change the results; the ρ value was 0.009 
for the correlation between oral β-blockers and AF.
Table 1 - Baseline characters in patients with AF and without AF
Variables AF (n = 92) Without AF (n = 1309) Odds Ratio ρ value *
Age (years) 70 +/- 10.3 63 +/- 12.8  < 0.001
Male gender (%) 65.2 73.4 2.92 NS
Diabetes mellitus (%) 38 27.3 1.64 0.026
Previous AMI (%) 41.3 27 1.91 0.003
CABG (%) 34.8 17.1 2.58 < 0.0001
PTCA (%) 26.1 36.8 0.61 0.038
LVEF (%) 0.43 +/- 16.4 0.51 +/- 15.3 < 0.001
Creatinine clearance 38.3 +/- 20.4 55.7 +/- 41.5 < 0.001
STEMI (%) 55.4 57.2 0.93 NS
Anterior AMI (%) 43.5 42.8 1.03 NS
β-Blocker (%) 48.9 63.8 0.54 0.004
ACE inhibitors (%) 54.3 50 1.19 NS
Aspirin (%) 94.6 94.3 1.06 NS
AF = atrial fibrillation; AMI = acute myocardial infarction; CABG = coronary artery bypass grafting; PTCA = percutaneous coronary angioplasty; LVEF 
= left ventricular ejection fraction; STEMI = ST elevation myocardial infarction; ACE = angiotensin-converting enzyme inhibitor; NS = not significant. 
* = ρ < 0.05.
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b.2. Mortality
As noted in Figure 1, 31.5% of the patients in the group 
that presented with AF died, compared to 9.2% in the group 
without arrhythmia (ρ < 0.001; Odds Ratio = 4.52). Figure 
1 clearly shows an inverse correlation between the use of 
β-blockers and mortality (17.5% mortality in patients who 
did not use β-blockers and 6.7% mortality in those that 
did; ρ < 0.001; OR = 0.34). LVEF and age also showed a 
correlation with mortality (Table 2). The incidence of death 
among women was 13.2% (50/380), while in males it was 
9.8% (100/1021, OR = 0.72, ρ = 0.07). Two hundred and 
forty patients used both oral and intravenous β-blockers. The 
results did not change when these patients were excluded. 
Values of ρ <0.001 were found for the correlations between 
mortality and the use of oral β-blockers, AF, and also found 
between use of oral β-blockers or presence of AF and 
mortality.
c. Adjusted Models 
c.1. Occurrence of AF
The patients who used β-blockers showed a lower risk 
of AF (OR = 0.59; ρ = 0.029) in the adjusted model. Age, 
coronary surgery and LVEF also had a significant correlation 
with the presence of AF, as shown in Table 3.
c.2. Mortality
The multivariate analysis of the association between 
different clinical variables and mortality is shown in Table 
4. The presence of AF was independently correlated with 
mortality (OR = 2.48, ρ = 0.002). The use of β-blockers was 
inversely and independently correlated with mortality (OR = 
0.52; ρ = 0.002). Table 4 also shows the correlation between 
mortality and age, LVEF, creatinine clearance and use of 
angiotensin-converting enzyme inhibitors.
Limitations
This study was a retrospective study based on a 
databank. However, the fact that the data were included 
prospectively decreases the chance of any bias related 
to the results. Due to retrospective design of the study, 
Figure 1 - The relationship between use of β-Blocker and AF with mortality. Legend: AF = atrial fibrilation. * = ρ < 0.001.
Table 2 - The relationship between age, ejection fraction and 
mortality LVEF = left ventricle ejection fraction
Age (years)* Ejection fraction of LVEF*
Deaths 72 +/- 11.9# 0.41 +/- 15.0#
Live 62 +/- 12.4# 0.52 +/- 15.1#
* = average; +/- standard deviation; # = ρ value <0.001.
Table 3 - Multivariate analysis of the association between 
different clinical variables and the occurrence of AF
Variables Odds Ratio CI 95% ρ value*
Age 1.045 1.024 – 1.067 < 0.0001
Diabetes mellitus 1.164 0.711 – 1.907 NS
Previous AMI 1.297 0.792 – 2.124 NS
CABG 3.085 1.886 – 5.057 < 0.0001
PTCA 0.925 0.531 – 1.611 NS
LVEF 0.968 0.952 – 0.983 < 0.001
Creatinine clearance 1.248 0.960 – 1.621 NS
STEMI 1.144 0.703 – 1.861 NS
Anterior AMI 1.008 0.621 – 1.634 NS
β-Blocker 0.59 0.367 – 0.948 0.029
ACE inhibitors 1.492 0.925 – 2.408 NS
Aspirin 0.9 0.328 – 2.471 NS
AF = atrial fibrillation; CI = confidence interval; AMI = acute myocardial 
infarction; CABG = coronary artery bypass grafting; PTCA = percutaneous 
coronary angioplasty; LVEF = left ventricular ejection fraction; STEMI = 
ST elevation myocardial infarction; ACE = angiotensin-converting enzyme 
inhibitor; NS = not significant. * = ρ < 0.05.
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some important data, including echocardiography 
parameters (ejection fraction, left atrial size, left ventricular 
hypertrophy, diastolic function), electrolyte levels and 
oxygen status are missing.
DISCUSSION 
In accordance with previous evidence, this sample 
showed a significant association between the use 
of β-blockers and reduction in mortality during the 
hospitalization of patients with AMI. In these results, the 
lack of β-blocker use was related to increased mortality and 
AF. This correlation remained significant even in adjusted 
models. Most studies that evaluated the effect of β-blockers 
after AMI reported a short-term reduction of up to 50% in 
the risk of death, similar to our results.1,3,5,6,8 However, there 
are no studies that clearly associated β-blockers, AF and in-
hospital mortality after an AMI. 
Dargie et al. conducted a randomized, multicenter, 
placebo-controlled study (CAPRICORN) examining the use 
of carvedilol in 1959 infarcted patients with left ventricular 
dysfunction (EF < 40%) over a period of 1.3 years. As 
expected, the observed mortality was lower in the group 
that received carvedilol than in the control group (12% 
vs. 15%, respectively, ρ = 0.03).9 Recently, the COMMIT/
CCS-2 study10,27 assessed the in-hospital use of intravenous 
metoprolol followed by oral treatment in 45,852 patients 
with ST-segment elevation AMI. Despite the reduction in 
ventricular arrhythmias in the β-blocker group, the drug was 
related to an increased risk of cardiogenic shock, especially 
in patients in Killip 3 and 4. These results raised some 
issues: should β-blockers be used orally or intravenously? 
Which mechanisms are responsible for the drug’s benefit? In 
what group of patients should we use the drug after AMI? In 
fact, a previous study, based on the GUSTO-1 trial, showed 
a larger benefit in patients who used oral β-blockers than in 
those who used intravenous followed by oral treatment.12 In 
our study, intravenous β-blockers was not better than oral 
treatment. In any case, all of the available evidence has led 
the most recent guidelines to suggest caution when using 
intravenous β-blockers after AMI.26
The analysis of AF after AMI showed that, as in 
previous publications, patients who had had an arrhythmia 
during hospitalization had an increased mortality rate 
(31% vs. 9.2%, ρ < 0.001).14,15,18-25 Laurent et al. conducted 
a retrospective study in patients with non-ST elevation 
AMI. The study showed that the occurrence of AF in 
the first 24 hours after AMI significantly increased in-
hospital mortality compared to patients who did not have 
the arrhythmia (21% vs. 6%, respectively, ρ = 0.03).21 In 
another retrospective study, Pedersen et al. observed that 
patients with left ventricular dysfunction who had AF after 
AMI also showed increased in-hospital mortality (OR = 
1.8, ρ <0.05).20 In a sub-analysis of the GUSTO-III trial, 
13,858 patients were assessed after AMI. Investigators 
correlated the occurrence of AF and prognosis. The 
mortality in patients with AF was greater than in the 
group without the arrhythmia [OR = 1.63 (1.31-2.02)].28 
Additionally, Asanin et al. demonstrated that the recurrence 
of AF during hospitalization for AMI further increases the 
risk of death compared to those with a single episode of 
arrhythmia (36.1% vs. 12.9%, respectively).14
Regarding the anti-arrhythmic effects of β-blockers, 
previous studies have shown controversial results regarding 
the ability of the drug to reduce the risk of AF after 
AMI.13,14,18,28,29 A study conducted by McCullough et 
al. prospectively examined the benefits of the use of 
β-blockers in 1724 patients after AMI with chronic renal 
failure. The authors reported a significant reduction 
in the incidence of AF in patients using β-blockers 
compared to patients who had not used the drug (9.5% 
vs. 16.4%, respectively, p < 0.0001).13 On the other hand, 
other major studies have found different results. The 
retrospective analysis of the AIRE study, which assessed 
the use of β-blockers in patients with AMI and ventricular 
dysfunction, showed reduced mortality but no differences 
in the incidence of arrhythmia in patients who used the 
drug.18 Similarly, Yilmaz et al. reported an AF incidence 
of 23.8% after AMI, without any reduction in the risk of 
Table 4 - Multivariate analysis of the association between 
different clinical variables and mortality
Variables Odds Ratio CI 95% ρ value*
Age 1.061 1.042 – 1.081 < 0.0001
Diabetes mellitus 1.097 0.703 – 1.712 NS
AF 2.476 1.399 – 4.382 0.002
Previous AMI 0.781 0.495 – 1.233 NS
CABG 1.222 0.720 – 2.075 NS
PTCA 0.703 0.436 – 1.133 NS
LVEF 0.955 0.940 – 0.969 < 0.001
Creatinine clearance 1.694 1.297 – 2.214 < 0.001
STEMI 1.127 0.732 – 1.737 NS
Anterior AMI 1.089 0.709 – 1.671 NS
β-Blocker 0.521 0.342 – 0.794 0.002
ACE inhibitors 0.481 0.312 – 0.740 0.001
Aspirin 1.027 0.451 – 2.337 NS
AF = atrial fibrillation; CI = confidence interval; AMI = acute myocardial 
infarction; CABG = coronary artery bypass grafting; PTCA = percutaneous 
coronary angioplasty; LVEF = left ventricular ejection fraction; STEMI = 
ST elevation myocardial infarction; ACE = angiotensin-converting enzyme 
inhibitor; NS = not significant. * = ρ < 0.05.
269
CLINICS 2010;65(3):265-70 β-blockers and fa in myocardial infarction
Pesaro AE ET AL.
arrhythmia in the group treated with β-blockers.29 On the 
other hand, our study found a significant increase in the 
incidence of AF in patients who had not used β-blockers 
compared to those who used the drug. Even after 
multivariate analysis, the risk of AF in patients who had not 
used β-blockers remained high and significant.
CONCLUSION 
The presence of AF and the absence of oral β-blocker use 
increased in-hospital mortality in patients with AMI. Oral 
β-blockers reduced the incidence of AF, a mechanism that 
might be at least partially responsible for the drug’s benefit.
REFERENCES
1. Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing 
the risk of events after acute myocardial infarction. Am J Cardiol. 
2006;98:1115-9. 
2. Stenestrand U, Lindback J, Wallentin L, RIKS-HIA Registry. 
Anticoagulation therapy in atrial fibrillation in combination with acute 
myocardial infarction influences long-term outcome: a prospective 
cohort study from the Register of Information and Knowledge About 
Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 
2005;112:3225-31.
3. Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect 
of metoprolol on the prognosis for patients with suspected acute 
myocardial infarction and indirect signs of congestive heart failure (a 
subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol. 
1997;80(9B):40J-44J.
4. Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA. 
Improving outcomes in post-acute myocardial infarction heart failure: 
incorporation of aldosterone blockade into combination therapy to 
optimize neurohormonal blockade. Am J Cardiol.;97(10A):26F-33F. 
5. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and 
angiotensin-converting enzyme inhibitor therapy in patients with 
end-stage renal disease and an acute myocardial infarction. J Am Coll 
Cardiol.;42:201-8.
6. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, 
et al. Early use of beta-blockers is associated with attenuation of serum 
C-reactive protein elevation and favorable short-term prognosis after 
acute myocardial infarction. Cardiology. 2003;99:47-53.
7. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J; 
OPTIMAAL Investigators. Effect of combined statin and beta-blocker 
treatment on one-year morbidity and mortality after acute myocardial 
infarction associated with heart failure. Am J Cardiol. 2004;93:603-6.
8. Weir R, McMurray JJ. Treatments that improve outcome in the patient 
with heart failure, left ventricular systolic dysfunction, or both after acute 
myocardial infarction. Heart. 2005;91 Suppl 2:ii17-20; discussion ii31, 
ii43-8.
9. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in 
patients with left-ventricular dysfunction: the CAPRICORN randomised 
trial. Lancet. 2001;357:1385-90.
10. III Diretriz sobre tratamento do infarto agudo do miocárdio. Arq Bras 
Cardiol. 2004 (83) Suplemento IV.
11. Garton M. COMMIT/CCS-2 studies. Lancet. 200619;368:642.
12. Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, 
Sgarbossa EB, et al. Non-Q-wave versus Q-wave myocardial infarction 
after thrombolytic therapy: angiographic and prognostic insights from 
the global utilization of streptokinase and tissue plasminogen activator 
for occluded coronary arteries-I angiographic substudy. GUSTO-I 
Angiographic Investigators. 1998;97:444-50.
13. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley 
HJ. Benefits of aspirin and beta-blockade after myocardial infarction in 
patients with chronic kidney disease. Am Heart J. 2002;144:226-32.
14. Asanin M, Perunicic J, Mrdovic I, Matic M, Vujisic-Tesic B, 
Arandjelovic A, et al. Significance of recurrences of new atrial fibrillation 
in acute myocardial infarction. Int J Cardiol. 200610;109:235-40. 
15. Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz 
R, et al. Previously known and newly diagnosed atrial fibrillation: a 
major risk indicator after a myocardial infarction complicated by heart 
failure or left ventricular dysfunction. Eur J Heart Fail. 2006;8:591-8. 
16. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et 
al. Management and outcome of patients with atrial fibrillation during 
acute myocardial infarction: the GUSTO-III experience. Global use of 
strategies to open occluded coronary arteries. Heart. 2002;88:357-62.
17. McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-
Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial 
infarction: results of the Carvedilol Post-Infarct Survival Control in 
Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 
200515;45:525-30.
18. Spargias KS, Hall AS, Greenwood DC, Ball SG. Beta blocker treatment 
and other prognostic variables in patients with clinical evidence of heart 
failure after acute myocardial infarction: evidence from the AIRE study. 
Heart. 1999;81:25-32.
19. Sakata K, Kurihara H, Iwamori K, Maki A, Yoshino H, Yanagisawa A, 
Ishikawa K. Clinical and prognostic significance of atrial fibrillation in 
acute myocardial infarction. Am J Cardiol. 1997;80:1522-7.
20. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C; FACC, on behalf 
of the TRACE Study Group. Impact of congestive heart failure and left 
ventricular systolic function on the prognostic significance of atrial 
fibrillation and atrial flutter following acute myocardial infarction. Int 
J Cardiol. 20058;100:65-71.
21. Laurent G, Zeller M, Dentan G, Moreau D, Laurent Y, Beer JC, et 
al. Prognostic impact of new onset atrial fibrillation in acute non-ST 
elevation myocardial infarction data from the RICO survey. Heart. 
200;91:369-70.
22. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh 
BJ, et al. Acute myocardial infarction complicated by atrial fibrillation 
in the elderly: prevalence and outcomes. Circulation. 2007;101:969-74.
23. Serrano CV Jr, Ramires JA, Mansur AP, Pileggi F. Importance of the time 
of onset of supraventricular tachyarrhythmias on prognosis of patients 
with acute myocardial infarction. Clin Cardiol. 1995;18:84-90.
270
CLINICS 2010;65(3):265-70β-blockers and fa in myocardial infarction
Pesaro AE ET AL.
24. Petrina M, Goodman SG, Eagle KA. The 12-lead electrocardiogram 
as a predictive tool of mortality after acute myocardial infarction: 
current status in an era of revascularization and reperfusion. Am Heart 
J. 2006;152:11-8.
25. Asanin M, Perunicic J, Mrdovic I, Matic M, Vujisic-Tesic B, 
Arandjelovic A, et al. Prognostic significance of new atrial fibrillation 
and its relation to heart failure following acute myocardial infarction. 
Eur J Heart Fail. 2005;7:671-6.
26. Canadian Cardiovascular Society, American Academy of Family 
Physicians, American College of Cardiology, American Heart 
Association, Antman EM, Hand M, et al. 2007 focused update of 
the ACC/AHA 2004 guidelines for the management of patients with 
ST-elevation myocardial infarction: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol. 2008;51:210-47.
27. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. 
Early intravenous then oral metoprolol in 45,852 patients with acute 
myocardial infarction: randomised placebo-controlled trial. Lancet. 
20055;366:1622-32. 
28. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et 
al. New atrial fibrillation after acute myocardial infarction independently 
predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878-
85.
29. Yilmaz R, Kasap H, Baykan M, Durmus I, Kaplan S, Celik 
S, et al. Assessment of left ventricular function by Doppler 
tissue imaging in patients with atrial fibrillation following 
acute myocardial infarction. Int J Cardiol. 2005;102:79-85. 
